...
首页> 外文期刊>Journal of biomedical materials research. Part B, Applied biomaterials. >Preseeding of human vascular cells in decellularized bovine pericardium scaffold for tissue-engineered heart valve: An in vitro and in vivo feasibility study.
【24h】

Preseeding of human vascular cells in decellularized bovine pericardium scaffold for tissue-engineered heart valve: An in vitro and in vivo feasibility study.

机译:用于组织工程化心脏瓣膜的脱细胞牛心包支架中人类血管细胞的预播:一项体外和体内可行性研究。

获取原文
获取原文并翻译 | 示例
           

摘要

Human vascular cells from saphenous veins have been used for cell seeding on the synthetic scaffolds for constructing tissue-engineered heart valve (TEHV). However, little is known about the seeding of human vascular cells on bovine pericardium, a potential natural scaffold for TEHV. This study was aimed to assess the basic in vitro and in vivo characteristics of the human vascular cells seeded on decellularized bovine pericardium. In vitro, bovine pericardium samples with cell seeding were inspected on day 7, 14, and 21 by histology, scanning electron microscopy, and immunohistochemistry. In vivo, experiments were performed in nude mice by bilateral dorsal incision for the implantation of decellularized bovine pericardium with and without cell seeding. Results demonstrated that a total of 8-10 × 10(6) cells were obtained within 4-5 wk by the primary co-culture, which were detected positive for von Willebrand factor, α-smooth muscle actin antibodies, and fibronectin, indicating the presence of endothelial cells, smooth muscle cells, and fibroblasts, respectively. In vitro, the seeded cells showed a steady increase of endothelial activity from day 1 to day 7 and remained stable until day 21. After 30 days of implantation in vivo, the cells on the decellularized bovine pericardium could differentiate directionally and show all the identities of human endothelial cells, smooth muscle cells, and fibroblasts. These results indicate that the human vascular cells from the saphenous vein are an optional cell source for seeding on decellularized bovine pericardium scaffold for constructing TEHV. ? 2012 Wiley Periodicals, Inc. J Biomed Mater Res Part B: Appl Biomater 100B: 1654-1661, 2012.
机译:来自隐静脉的人类血管细胞已被用于在合成支架上的细胞接种,以构建组织工程性心脏瓣膜(TEHV)。然而,关于人血管细胞在牛心包膜上的种子知之甚少,牛心包膜是TEHV的潜在天然支架。这项研究旨在评估接种在脱细胞牛心包上的人血管细胞的基本体外和体内特性。在体外,在第7、14和21天通过组织学,扫描电子显微镜和免疫组织化学检查带有细胞接种的牛心包样品。在体内,通过双侧背侧切口在裸鼠中进行有细胞和无细胞植入的脱细胞牛心包的植入实验。结果表明,通过一次共培养,在4-5周内总共获得了8-10×10(6)个细胞,这些细胞被检测出对von Willebrand因子,α-平滑肌肌动蛋白抗体和纤连蛋白呈阳性。分别存在内皮细胞,平滑肌细胞和成纤维细胞。在体外,从第1天到第7天,接种的细胞显示出内皮活性的稳定增加,直到第21天都保持稳定。在体内植入30天后,去细胞牛心包膜上的细胞可以定向分化并显示出所有特征。人内皮细胞,平滑肌细胞和成纤维细胞。这些结果表明,来自隐静脉的人血管细胞是用于接种在脱细胞牛心包支架上以构建TEHV的可选细胞来源。 ? 2012 Wiley Periodicals,Inc. J Biomed Mater Res B部分:Appl Biomater 100B:1654-1661,2012。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号